A New Agent in Prevention of Contrast-Induced Nephropathy: Dragon Fruit (Hylocereus polyrhizus) Extract

Abstract

Purpose: We aimed to investigate dragon fruit (Hylocereus polyrhizus) extract effectiveness by creating a nephropathy model with contrast media toxicity after dehydration and furosemide administration to rats. Methods: Total 36 male Sprague dawley rats were randomly allocated into 6 groups (n: 6). At the end of the experiment kidney organs and blood was taken for histopathologic and biochemical analyze (malondialdehyde, glutathione, serum urea nitrogen and serum creatine). Results: Renal injury markers of serum urea nitrogen and creatinine levels decreased (p<0.05) in the groups that given dragon fruit extract depending on the dose manner compared to the group that was given contrast media. While oxidative stress increased in given contrast media group, MDA levels improved statistically significance in the groups given dragon fruit extract depending on the dose compared to the group that was given contrast media. Also tissue GSH levels increased in the groups given dragon fruit extract depending on the dose compared to the group that was given contrast media. Vacuolization damage was minimal and inflammation was not seen in these groups according to the histopathological analyses. Conclusion: Dragon fruit extract, a strong antioxidative agent, application together with contrast media can play a protective role against renal tubule via reduced renal injury markers, oxidative damage.

Keywords

• Contrast induced nephropathy
• dragon fruit extract
• kidney
• oxidative stress
• rat

References

1. 1. Li PK, Burdmann EA, Mehta RL. World Kidney Day 2013: acute kidney injury-global health alert. American journal of kidney diseases : the official journal of the National Kidney Foundation 2013;61:3:359-63. Doi:10.1053/j.ajkd.2013.01.002
2. 2. Itoh Y, Yano T, Sendo T, Oishi R. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. Journal of pharmacological sciences 2005;97:4:473-88. Doi:10.1254/jphs.crj05002x
3. 3. Jabara R, Gadesam RR, Pendyala LK, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. The American journal of cardiology 2009;103:12:1657-62. Doi:10.1016/j.amjcard.2009.02.039
4. 4. Sendeski MM. Pathophysiology of renal tissue damage by iodinated contrast media. Clinical and experimental pharmacology & physiology 2011;38:5:292-9. Doi:10.1111/j.1440-1681.2011.05503.x
5. 5. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Investigative radiology 2002;37:8:428-34. Doi:10.1097/00004424-200208000-00003
6. 6. Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Investigative radiology 2010;45:4:188-95. Doi:10.1097/RLI.0b013e3181d2eed8
7. 7. Faggioni M, Mehran R. Preventing Contrast-induced Renal Failure: A Guide. Interventional cardiology 2016;11:2:98-104. Doi:10.15420/icr.2016:10:2
8. 8. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:18:2837-42. Doi:10.1161/01.CIR.0000146396.19081.73

9. 9. Pannu N, Wiebe N, Tonelli M, Alberta Kidney Disease N. Prophylaxis strategies for contrast-induced nephropathy. Jama 2006;295:23:2765-79. Doi:10.1001/jama.295.23.2765
10. 10. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. The New England journal of medicine 2006;354:26:2773-82. Doi:10.1056/NEJMoa054209
11. 11. Colbay M, Yuksel S, Uslan I, et al. Novel approach for the prevention of contrast nephropathy. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 2010;62:1:81-9. Doi:10.1016/j.etp.2009.02.119
12. 12. Onbasili AO, Yeniceriglu Y, Agaoglu P, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007;93:6:698-702. Doi:10.1136/hrt.2006.097477
13. 13. Yoshida S, Kamihata H, Nakamura S, et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. Journal of cardiology 2009;54:2:192-8. Doi:10.1016/j.jjcc.2009.05.006
14. 14. Macias-Ceja DC, Cosin-Roger J, Ortiz-Masia D, et al. The flesh ethanolic extract of Hylocereus polyrhizus exerts anti-inflammatory effects and prevents murine colitis. Clinical nutrition 2016;35:6:1333-9. Doi:10.1016/j.clnu.2016.02.013
15. 15. Wu L-c, Hsu H-W, Chen Y-C, Chiu C-C, Lin Y-I, Ho J-aA. Antioxidant and antiproliferative activities of red pitaya. Food Chemistry 2006;95:2:319-27
16. 16. Zainoldin Kh, Baba AS. The Effect Of Hylocereus Polyrhizus And Hylocereus Undatus On Physicochemical, Proteolysis, And Antioxidant Activity In Yogurt. World Academy of Science, Engineering and Technology 2009;60:361-6
17. 17. Castro-Enriquez DD, Montano-Leyva B, Del Toro-Sanchez CL, et al. Effect of Ultrafiltration of Pitaya Extract (Stenocereus thurberi) on Its Phytochemical Content, Antioxidant Capacity, and UPLC-DAD-MS Profile. Molecules 2020;25:2. Doi:10.3390/molecules25020281
18. 18. Hartono MR, Suardita K, Yuliati A. Proliferation and osteogenic differentiation of bone marrow-derived mesenchymal stem cell after exposure to red flesh dragon fruit extract. Dental research journal 2020;17:2:107-13
19. 19. Som AM, Ahmat N, Abdul Hamid HA, Azizuddin N. A comparative study on foliage and peels of Hylocereus undatus (white dragon fruit) regarding their antioxidant activity and phenolic content. Heliyon 2019;5:2:e01244. Doi:10.1016/j.heliyon.2019.e01244
20. 20. Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. American journal of obstetrics and gynecology 1979;135:3:372-6. Doi:10.1016/0002-9378(79)90708-7
21. 21. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. The Journal of laboratory and clinical medicine 1963;61:882-8
22. 22. Akgullu C, Hekim T, Eryilmaz U, et al. The usefulness of carvedilol and nebivolol in preventing contrast nephropathy in rats. Renal failure 2015;37:3:511-7. Doi:10.3109/0886022X.2015.1006087
23. 23. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:19:2259-64. Doi:10.1161/01.cir.0000016043.87291.33
24. 24. Kim H, Choi HK, Moon JY, Kim YS, Mosaddik A, Cho SK. Comparative antioxidant and antiproliferative activities of red and white pitayas and their correlation with flavonoid and polyphenol content. Journal of food science 2011;76:1:C38-45. Doi:10.1111/j.1750-3841.2010.01908.x
25. 25. Morais SGG, da Silva Campelo Borges G, Dos Santos Lima M, Martin-Belloso O, Magnani M. Effects of probiotics on the content and bioaccessibility of phenolic compounds in red pitaya pulp. Food research international 2019;126:108681. Doi:10.1016/j.foodres.2019.108681
26. 26. Boyacioglu M, Turgut H, Akgullu C, Eryilmaz U, Kum C, Onbasili OA. The effect of L-carnitine on oxidative stress responses of experimental contrast-induced nephropathy in rats. The Journal of veterinary medical science 2014;76:1:1-8. Doi:10.1292/jvms.13-0202
27. 27. Kongkham S, Sriwong S, Tasanarong A. Protective effect of alpha tocopherol on contrast-induced nephropathy in rats. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2013;33:1:116-23. Doi:10.3265/Nefrologia.pre2012.Nov.11736
28. 28. Aksu F, Aksu B, Unlu N, et al. Antioxidant and renoprotective effects of sphingosylphosphorylcholine on contrast-induced nephropathy in rats. Renal failure 2016;38:7:1089-98. Doi:10.1080/0886022X.2016.1194142
29. 29. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. The New England journal of medicine 2003;348:6:491-9. Doi:10.1056/NEJMoa021833
30. 30. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. The World Allergy Organization journal 2012;5:1:9-19. Doi:10.1097/WOX.0b013e3182439613
31. 31. Ari E, Kedrah AE, Alahdab Y, et al. Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. The British journal of radiology 2012;85:1016:1038-43. Doi:10.1259/bjr/16327485
32. 32. Toprak O, Cirit M, Tanrisev M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2008;23:3:853-9. Doi:10.1093/ndt/gfm691
33. 33. Rebecca O, Boyce A, Chandran S. Pigment identification and antioxidant properties of red dragon fruit (Hylocereus polyrhizus). African Journal of Biotechnology 2010;9:10:1450-4
34. 34. Jones DP. Radical-free biology of oxidative stress. American journal of physiology Cell physiology 2008;295:4:C849-68. Doi:10.1152/ajpcell.00283.2008
35. 35. Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox biology 2013;1:483-91. Doi:10.1016/j.redox.2013.07.006
36. 36. Buyuklu M, Kandemir FM, Ozkaraca M, Set T, Bakirci EM, Topal E. Protective effect of curcumin against contrast induced nephropathy in rat kidney: what is happening to oxidative stress, inflammation, autophagy and apoptosis? European review for medical and pharmacological sciences 2014;18:4:461-70
37. 37. Vijayakumar R, Abd Gani SS, Zaidan UH, Halmi MIE, Karunakaran T, Hamdan MR. Exploring the Potential Use of Hylocereus polyrhizus Peels as a Source of Cosmeceutical Sunscreen Agent for Its Antioxidant and Photoprotective Properties. Evidence-based complementary and alternative medicine : eCAM 2020;2020:7520736. Doi:10.1155/2020/7520736
38. 38. Kiss N, Hamar P. Histopathological Evaluation of Contrast-Induced Acute Kidney Injury Rodent Models. BioMed research international 2016;2016:3763250. Doi:10.1155/2016/3763250
39. 39. Matsuzawa T, Nomura M, Unno T. Clinical pathology reference ranges of laboratory animals. Working Group II, Nonclinical Safety Evaluation Subcommittee of the Japan Pharmaceutical Manufacturers Association. The Journal of veterinary medical science 1993;55:3:351-62. Doi:10.1292/jvms.55.351